<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p39" style="overflow: hidden; position: relative; background-color: white; width: 433px; height: 649px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_39{left:411px;top:233px;letter-spacing:-0.1px;}
#t2_39{left:411px;top:78px;letter-spacing:-0.3px;}
#t3_39{left:415px;top:630px;letter-spacing:-1.1px;}
#t4_39{left:74px;top:40px;letter-spacing:-1px;}
#t5_39{left:80px;top:40px;letter-spacing:-1px;word-spacing:3.6px;}
#t6_39{left:80px;top:56px;letter-spacing:-1px;word-spacing:4px;}
#t7_39{left:80px;top:71px;letter-spacing:-1px;word-spacing:-0.1px;}
#t8_39{left:65px;top:106px;letter-spacing:-1px;}
#t9_39{left:72px;top:106px;letter-spacing:-1px;word-spacing:-0.1px;}
#ta_39{left:72px;top:121px;letter-spacing:-1px;word-spacing:-0.2px;}
#tb_39{left:74px;top:138px;letter-spacing:-1px;}
#tc_39{left:80px;top:138px;letter-spacing:-1px;word-spacing:5.5px;}
#td_39{left:80px;top:154px;letter-spacing:-1px;word-spacing:-0.1px;}
#te_39{left:74px;top:171px;letter-spacing:-1px;word-spacing:-0.2px;}
#tf_39{left:74px;top:189px;letter-spacing:-1px;}
#tg_39{left:80px;top:189px;letter-spacing:-1px;word-spacing:9.8px;}
#th_39{left:80px;top:204px;letter-spacing:-1px;word-spacing:4.3px;}
#ti_39{left:80px;top:219px;letter-spacing:-1px;}
#tj_39{left:109px;top:219px;letter-spacing:-1px;word-spacing:-0.2px;}
#tk_39{left:65px;top:254px;letter-spacing:-1px;word-spacing:-0.2px;}
#tl_39{left:65px;top:269px;letter-spacing:-1px;}
#tm_39{left:74px;top:287px;letter-spacing:-1px;}
#tn_39{left:80px;top:287px;letter-spacing:-1px;word-spacing:-1.8px;}
#to_39{left:80px;top:302px;letter-spacing:-1px;}
#tp_39{left:74px;top:319px;letter-spacing:-1px;}
#tq_39{left:80px;top:319px;letter-spacing:-1px;}
#tr_39{left:80px;top:335px;letter-spacing:-0.9px;word-spacing:2.6px;}
#ts_39{left:80px;top:350px;letter-spacing:-1px;word-spacing:6.7px;}
#tt_39{left:80px;top:365px;letter-spacing:-1px;word-spacing:-0.1px;}
#tu_39{left:74px;top:383px;letter-spacing:-1px;}
#tv_39{left:80px;top:383px;letter-spacing:-1px;word-spacing:0.1px;}
#tw_39{left:80px;top:398px;letter-spacing:-0.9px;word-spacing:-0.2px;}
#tx_39{left:65px;top:432px;letter-spacing:-1px;word-spacing:-0.3px;}
#ty_39{left:74px;top:450px;letter-spacing:-1px;}
#tz_39{left:80px;top:450px;letter-spacing:-1px;word-spacing:1.7px;}
#t10_39{left:80px;top:465px;letter-spacing:-1px;word-spacing:-0.1px;}
#t11_39{left:74px;top:482px;letter-spacing:-1px;}
#t12_39{left:80px;top:482px;letter-spacing:-1px;word-spacing:0.6px;}
#t13_39{left:80px;top:498px;letter-spacing:-1px;word-spacing:1px;}
#t14_39{left:131px;top:498px;letter-spacing:-1px;word-spacing:1.1px;}
#t15_39{left:80px;top:513px;letter-spacing:-1px;word-spacing:-0.1px;}
#t16_39{left:74px;top:530px;letter-spacing:-1px;}
#t17_39{left:80px;top:530px;letter-spacing:-0.9px;word-spacing:7.1px;}
#t18_39{left:80px;top:546px;letter-spacing:-1px;}
#t19_39{left:74px;top:563px;letter-spacing:-1px;}
#t1a_39{left:80px;top:563px;letter-spacing:-1px;word-spacing:0.3px;}
#t1b_39{left:80px;top:578px;letter-spacing:-1px;}
#t1c_39{left:110px;top:578px;letter-spacing:-1px;word-spacing:-0.2px;}
#t1d_39{left:74px;top:596px;letter-spacing:-1px;word-spacing:-0.1px;}

.s1_39{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(156,100,158);
}

.s2_39{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(35,31,32);
}

.s3_39{
	FONT-SIZE: 37.6px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(255,255,255);
}

.s4_39{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s5_39{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed-Bold_j0;
	color: rgb(35,31,32);
}

.t.m0_39{
	-webkit-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-ms-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-moz-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-o-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts39" type="text/css" >

@font-face {
	font-family: Helvetica-Condensed-Bold_j0;
	src: url("fonts/Helvetica-Condensed-Bold_j0.woff") format("woff");
}

@font-face {
	font-family: AllerDisplay_lq;
	src: url("fonts/AllerDisplay_lq.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed_ix;
	src: url("fonts/Helvetica-Condensed_ix.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg39Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg39" style="-webkit-user-select: none;"><object width="433" height="649" data="39/39.svg" type="image/svg+xml" id="pdf39" style="width:433px; height:649px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_39" class="t m0_39 s1_39">O Guia do Jovem Internista </div>
<div id="t2_39" class="t m0_39 s2_39">2016</div>
<div id="t3_39" class="t s3_39">37</div>
<div id="t4_39" class="t s4_39">- </div>
<div id="t5_39" class="t s4_39">Em caso de doentes de alto risco (troponina elevada, trombo visí-</div>
<div id="t6_39" class="t s4_39">vel), é recomendado adicionar um inibidor GP IIb/IIIa se risco he-</div>
<div id="t7_39" class="t s4_39">morrágico baixo</div>
<div id="t8_39" class="t s4_39">• </div>
<div id="t9_39" class="t s4_39">Anticoagulação - mantida até 24 horas após ICP ou alta clínica/ 8 dias </div>
<div id="ta_39" class="t s4_39">em caso de estratégia conservadora.</div>
<div id="tb_39" class="t s4_39">- </div>
<div id="tc_39" class="t s4_39">Enoxaparina 1 mg/Kg sc de 12 em 12 horas - ajustar a dose em </div>
<div id="td_39" class="t s4_39">doentes com ClCreat &lt; 30 mL/min</div>
<div id="te_39" class="t s4_39">- Fondaparinux 2,5 mg/dia sc.</div>
<div id="tf_39" class="t s4_39">- </div>
<div id="tg_39" class="t s4_39">Heparina não fraccionada: bólus ev 60-70 U/kg (máx 5000 UI), </div>
<div id="th_39" class="t s4_39">seguida de infusão 12-15 U/kg/hora (máx 1000U/hora) ajustada a </div>
<div id="ti_39" class="t s4_39">aPTT </div>
<div id="tj_39" class="t s4_39">alvo 50-70s</div>
<div id="tk_39" class="t s4_39">Recomendações para estratégia invasiva de revascularização EAM sem </div>
<div id="tl_39" class="t s4_39">supra-ST:</div>
<div id="tm_39" class="t s4_39">- </div>
<div id="tn_39" class="t s4_39">Estratégia invasiva urgente (&lt; 120 min) em doentes com risco muito </div>
<div id="to_39" class="t s4_39">elevado.</div>
<div id="tp_39" class="t s4_39">- </div>
<div id="tq_39" class="t s4_39">Estratégia invasiva precoce (&lt; 24 horas): doentes com scores GRA-</div>
<div id="tr_39" class="t s4_39">CE &gt; 140, ou um critério de alto risco primário (subida ou descida </div>
<div id="ts_39" class="t s4_39">significativa das troponinas e alterações dinâmicas da onda T ou </div>
<div id="tt_39" class="t s4_39">segmento ST)</div>
<div id="tu_39" class="t s4_39">- </div>
<div id="tv_39" class="t s4_39">Estratégia invasiva (&lt; 72 horas): doentes com pelo menos 1 critério </div>
<div id="tw_39" class="t s4_39">de alto risco e sintomas recorrentes. </div>
<div id="tx_39" class="t s5_39">• Prevenção secundária:</div>
<div id="ty_39" class="t s4_39">- </div>
<div id="tz_39" class="t s4_39">Beta-bloqueantes em todos os doentes com função sistólica do VE </div>
<div id="t10_39" class="t s4_39">diminuída (FejVE&lt; 40%)</div>
<div id="t11_39" class="t s4_39">- </div>
<div id="t12_39" class="t s4_39">IECA nas primeiras 24 horas e lifelong se FejVE&lt;40% e IC sintomá-</div>
<div id="t13_39" class="t s4_39">tica, HTA, </div>
<div id="t14_39" class="t s4_39">diabetes ou insuficiência renal; também se EAM anterior </div>
<div id="t15_39" class="t s4_39">nos doentes com EAM com supraST;</div>
<div id="t16_39" class="t s4_39">- </div>
<div id="t17_39" class="t s4_39">ARA nos doentes com indicação para IECA mas intolerância aos </div>
<div id="t18_39" class="t s4_39">mesmos</div>
<div id="t19_39" class="t s4_39">- </div>
<div id="t1a_39" class="t s4_39">Antagonistas da aldosterona - indicados se F.Ejeção &lt; 40%, IC, dia-</div>
<div id="t1b_39" class="t s4_39">betes </div>
<div id="t1c_39" class="t s4_39">e se não existir insuficiência renal ou hipercaliémia.</div>
<div id="t1d_39" class="t s4_39">- Estatinas em alta dose. Objectivo LDL &lt;70mg/dL.</div>

<!-- End text definitions -->


</div>
</body>
</html>
